Business
AZN: FY16 and Q4 2016 Results
AZN: FY16 and Q4 2016 Results.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n \nRNS Number : 8083V AstraZeneca PLC 02 February 2017 \n\nAstraZeneca PLC \n2 February 2017 07:00\n \nFull-Year and Q4 2016 Results \nPerformance in line with expectations; 2017 has the potential to be a defining year \n \nFinancial Summary\n\n\n\n\n\n\n\nFY 2016\n\n\n\n\n\nQ4 2016\n\n\n\n\n\n\n\n$m\n\n\n% change\n\n\n$m \n\n\n% change\n\n\n\n\n\n\n\nCER1\n\n\nActual\n\n\nCER\n\n\nActual\n\n\n\n\nTotal Revenue\n\n\n23,002\n\n\n(5)\n\n\n(7)\n\n\n5,585\n\n\n(12)\n\n\n(13)\n\n\n\n\nProduct Sales\n\n\n21,319\n\n\n(8)\n\n\n(10)\n\n\n5,260\n\n\n(15)\n\n\n(15)\n\n\n\n\nExternalisation Revenue\n\n\n1,683\n\n\n59\n\n\n58\n\n\n325\n\n\n77\n\n\n69\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nReported Operating Profit\n\n\n4,902\n\n\n9\n\n\n19\n\n\n2,533\n\n\nn/m\n\n\nn/m\n\n\n\n\nCore Operating Profit2\n\n\n6,721\n\n\n(7)\n\n\n(3)\n\n\n2,026\n\n\n15\n\n\n30\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nReported Earnings Per Share (EPS)\n\n\n$2.77\n\n\n9\n\n\n24\n\n\n$1.46\n\n\n93\n\n\nn/m\n\n\n\n\nCore EPS\n\n\n$4.31\n\n\n(5)\n\n\n1\n\n\n\n\n\n$1.21\n\n\n9\n\n\n29\n\n\n\n\n \n· The fall in Product Sales primarily reflected the entry of Crestor generic medicines in the US; Crestor represents the last anticipated blockbuster3 patent expiry, ahead of significant late-stage pipeline news flow \n· Good progress on cost control in the year, reflecting the evolving shape of the business: \n- Reported and Core R&D cost growth of 2% to $5,890m and 5% to $5,631m, respectively, including the absorption of the R&D costs of Acerta Pharma and ZS Pharma\n- Reported and Core SG&A costs declined by 12% to $9,413m and by 9% to $8,169m, respectively\n· Reported EPS increased by 9% in the year to $2.77, reflecting a revaluation of acquisition-related liabilities. A 5% fall in Core EPS was driven by a corresponding rate of decline in Total Revenue \n· A second interim dividend of $1.90 per share has been declared, bringing the dividend for the full year to $2.80 per share. The Board reaffirms its commitment to the Company's progressive dividend policy \n \n \nCommercial Highlights \nThe Growth Platforms grew by 5% in the year (Q4 2016: Up...